Archive · Business Recorder
GLP-1 boom in China, India, Brazil could create $22bn market by 2035, J.P. Morgan says
The combined China-India-Brazil market for weight-loss drugs could grow to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimated, as improving affordability and broader access drive adoption in largely untapped patient populations. The addressable market could grow at an annual rate of 15% through 2035, J.P. Morgan analysts led by Yang Huang said in a note on Friday, given the countries’ large diabetes and obesity burdens. GLP-1 drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound, have become some of the most sought-after medicines for weight-loss and dia...
ZAZTEK archives the headline, summary and publication date so the story stays findable. The full article remains the publisher's. Read it at Business Recorder →